ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.
Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.
Cohance Lifesciences announced a $18 million investment across two subsidiaries, NJ Bio and Aruka Bio, to strengthen its ADC strategy and commercial integration.
Cohance Lifesciences has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 in compliance with SEBI regulations. The report is available on the website.
Cohance Lifesciences Limited submitted its Integrated Annual Report for FY 2025-26. The report includes the notice for the company's 8th Annual General Meeting.
Cohance Lifesciences Limited will conduct its 8th Annual General Meeting on 17 September 2026 via video conference. The agenda includes adopting financial statements and director reappointment.
Cohance Lifesciences has withdrawn its credit ratings from CRISIL Ratings Limited for certain loan facilities. The company continues to maintain valid ratings from India Ratings.
DSP Trustee Pvt Ltd sold 2,899,996 shares of Cohance Lifesciences Ltd via open market. The total holding decreased from 4.29% to 3.53%.
Cohance reported its lowest-ever quarter, plagued by customer shipment phasing and biotech funding delays, resulting in a 23% revenue decline. Management frames this as a trough, banking on H2 recovery through restocked commercial molecules.
Cohance Lifesciences completed a USFDA inspection at its Pashamylaram facility, receiving five observations in Form FDA 483. None of the observations relate to data integrity issues.
Cohance reported a weak Q1FY27 with revenue at INR 4,223 Mn (-23.1% YoY) and adjusted EBITDA at INR 92 Mn (2.2% margin) due to phasing.
Cohance Lifesciences reported Q1FY27 revenue from operations of ₹4,223 million, down 23.1% year-on-year. The company noted weak performance and expects improvement in the second half.
Cohance Lifesciences Ltd reported revenue from operations of ₹422.3 Cr (-23.1% YoY) and a net loss of ₹45.2 Cr for Q1 FY27.
Cohance Lifesciences granted employee stock options under ESOP 2026 and ESOP 2023, while also allotting equity shares upon the exercise of vested options.
Cohance Lifesciences scheduled a board meeting for August 5, 2026. The board will consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Cohance Lifesciences provided a clarification to the NSE regarding their financial results filing, confirming submission of the required XBRL and non-machine readable format documents.
Cohance Lifesciences clarified that no pending information exists regarding the recent increase in trading volume. The company remains compliant with SEBI regulations.
Cohance Lifesciences shareholders approved all five resolutions via postal ballot. The resolutions include appointment of Chairman and CEO, remuneration, and ESOP plans.
Cohance Lifesciences Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. The report notes a procedural delay in filing XBRL financial results with BSE.
Cohance Lifesciences issued a postal ballot notice for appointing Mr. Umang Vohra as Chairman and CEO. Shareholders will also vote on a new ESOP 2026 plan.
Cohance Lifesciences Ltd reported revenue from operations of ₹619.1 Cr (-26.3% YoY) and net profit of ₹8.3 Cr (-92.9% YoY) for Q4 FY26.
Management is navigating a transition phase with significant revenue and margin pressure due to destocking and site disruptions. New CEO Umang Vohra focuses on embedding the company into global new drug value chains.
Cohance Lifesciences reported audited FY26 consolidated revenue of ₹2,268.55 Crore. The board also revised authorized personnel for determining materiality effective May 12, 2026.
Cohance Lifesciences Ltd has scheduled a Board Meeting on May 12, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed until May 14, 2026.
Cohance Lifesciences Limited clarified that there is no undisclosed information or event causing the recent share price movement. The company confirmed it remains compliant with SEBI disclosure regulations, having previously intimated the outcome of its April 27, 2026, board meeting.
Cohance Lifesciences Limited has appointed Mr. Umang Vohra as Chairman effective May 1, 2026. This follows the resignation of Mr. Vivek Sharma as Executive Chairman on April 30, 2026, due to personal reasons. Mr. Vohra brings over 30 years of experience, including leadership roles at Cipla and Dr. Reddy's.
Cohance Lifesciences Limited has appointed Mr. Umang Vohra as Chairman and Group CEO. Mr. Vohra brings over 30 years of experience, including leadership roles at Cipla, Dr. Reddy's Laboratories, and PepsiCo India.
Cohance Lifesciences appointed Umang Vohra as Executive Chairman (effective May 1, 2026) and Group CEO (effective May 20, 2026). He succeeds Vivek Sharma, who is stepping down for personal reasons but will remain as an advisor for nine months to ensure a smooth transition. Mr. Vohra previously served as MD and CEO of Cipla.